The platform to reliably control the world's #1 preventable cause of death. A single cheek swab guides how high blood pressure is best treated: whether renal denervation will work, and if it is the more traditional route of medications, which one is best for each patient.
Non-invasive collection from home or office.
We analyze only the genetic sites relevant to blood-pressure response, then destroy the sample.
Processed at a CAP-accredited, CLIA-certified genomics core, with results in as little as 48 hours.
Integrated Computational Genomic Medicine, weighted across the cardiac, renal, and vascular systems that set blood pressure.
Two granted U.S. patents cover the multi-gene weighted-algorithm methods behind both programs: predicting renal denervation response (No. 12,351,873) and selecting antihypertensive medications (No. 11,761,043).
A one-page report tailored to the decision: for renal denervation, a responder score showing how likely a patient is to respond; for medications, the drug or drugs most likely to work.
This goes beyond drug-metabolism testing. Geneticure is Integrated Computational Genomic Medicine (ICGM): an inch-wide, mile-deep genetic window to individual physiology.
RDN is a minimally invasive, FDA-approved procedure that lowers blood pressure, with Medicare coverage under Coverage with Evidence Development. But we believe wider adoption depends on better patient selection. Roughly 20 to 30% of patients see no benefit or a rise in blood pressure. Identifying likely responders in advance is what turns a promising procedure into a confident treatment decision.
7 see meaningful benefit. 3 see no benefit, or worsen.
Patients with the highest scores, who our algorithm predicted would respond, had the greatest blood pressure reduction with RDN.
Our algorithm flagged nearly every patient who went on to respond, and the group it scored highest still separated clearly from the group it scored lowest once the sham arm was accounted for.
N=29 blinded study. Patients recruited at Stanford, Baylor, Penn, Ascension; Geneticure blinded to responder status.
Ruling out likely non-responders raises the expected benefit for the treated population, and higher expected benefit brings a larger group forward.
* Illustrative adoption scenario, not observed utilization. Assumes ~30% RDN non-response without selection, 70% of patients screening in as likely responders, and near-complete response among those selected. Willingness figures from a published patient-preference survey (2021): Medtronic Patient Preferences for the Treatment of Hypertension, presented at TCT 2021 (Kandzari DE et al., discrete choice experiment).
If validated at scale, this becomes the default starting point for hypertension treatment. The same swab, the same platform: a second engine addressing 120M U.S. patients.
4 clinical trials (largely retrospective) · 8 peer-reviewed publications
DNA paired with historical medical claims; therapy concordant with Geneticure recommendations compared to discordant.
Advisors: Bruce D. Johnson, PhD (Professor of Medicine & Physiology, Mayo Clinic; NIH-funded genetics & cardiorespiratory lab) · Brad Wilson (CEO Emeritus, BCBS-NC) · Scott J. Dylla, PhD (former Co-Founder & CSO of Stemcentrx, acq'd by ABBV in 2016) · Joseph Falsone, MD, FACC (cardiologist, North Carolina Heart & Vascular) · Jordan Lipton, MD (co-founder, Signature Healthcare; emergency & concierge medicine).
Investors include: Mayo Clinic, Stanford University, Fairview Health, Xcellerant Ventures, M25, Wireframe Ventures, Western Skies Partners.
Geneticure goes well beyond drug metabolism, assessing hypertension treatment across the heart, blood vessels, and kidneys. The full evidence base is below.
For partnership inquiries, send a note and we'll follow up with you.